Pregabalin controlled release (Pfizer) success in Phase III study in Fibromyalgia

Top-line results were announced by Pfizer of a double-blind, Phase III study evaluating pregabalin controlled-release (CR) formulation in patients with Fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR). Fibromyalgia is a common pain condition in the United States, affecting more than five million Americans. It is characterized by chronic widespread pain and tenderness lasting for three or more months. This study is the second of three Phase III studies of the pregabalin CR formulation to report top-line findings, which will ascertain the potential use of pregabalin as a once-a-day therapy